Phrenix Therapeutics
Latest round
- Seed
Last raised
- Feb 2025
Total raised
- Undisclosed
Investors
- 2
About Phrenix Therapeutics
Founded in 2022, Phrenix Therapeutics specializes in creating innovative therapies that address severe psychiatric and neurological conditions. The firm is based in Australia and has completed two notable deals since its inception. The company was co-founded by Chris Langmead (CEO), Greg Stewart, and Jess Nithianantharajah.Bio and Brandon Capital Partners. Phrenix Therapeutics specializes in the development of G protein-coupled receptor (GPCR) targeted therapeutics aimed at addressing cognitive, psychiatric, and neurological disorders. By employing structure-guided design and disease-relevant analytical pharmacology, the company’s core offerings are therapeutics that seek to improve clinical outcomes for patients suffering from these conditions. Utilizing innovative rodent touchscreen-based technologies, Phrenix evaluates therapeutic targets and assesses the efficacy of pro-cognitive compounds, ensuring that their research reflects real-world clinical scenarios rather than historical methodologies. The end users of these products include individuals affected by various psychiatric and neurological disorders, as well as healthcare providers looking for advanced treatment options. Phrenix Therapeutics primarily aims to serve markets where there is a significant demand for improved psychiatric and neurological treatment solutions, including North America, Europe, and Australia. Revenue generation is structured around strategic partnerships and collaborations with research institutions and healthcare providers, focusing on delivering advanced therapeutic solutions. The company engages in B2B transactions, collaborating directly with healthcare professionals and institutions interested in its GPCR-targeted therapeutics.Bio and Brandon Capital Partners. Future growth plans include the launch of new GPCR-targeted therapeutics aimed at enhancing patient outcomes in cognitive health, although specific product release dates have not been disclosed. Phrenix also aims to expand into new geographic regions, specifically targeting North America and Europe by 2026.
Who invested in Phrenix Therapeutics
2 investors across 1 round
See all investors in Phrenix Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Feb 3, 2025
Amount
Undisclosed
Investors
Questions about Phrenix Therapeutics
Who invested in Phrenix Therapeutics?
Phrenix Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Phrenix Therapeutics raised?
Phrenix Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Phrenix Therapeutics last raise money?
Phrenix Therapeutics's most recent round on record is a Seed, in Feb 2025.
What does Phrenix Therapeutics do?
Founded in 2022, Phrenix Therapeutics specializes in creating innovative therapies that address severe psychiatric and neurological conditions.
Where is Phrenix Therapeutics headquartered?
Phrenix Therapeutics is headquartered in Australia.
Which VCs invest in companies like Phrenix Therapeutics?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Immutable Ventures back biotechnology companies at Phrenix Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Phrenix Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.